<DOC>
	<DOC>NCT01600365</DOC>
	<brief_summary>The purpose of this study is to study the use of ganciclovir gel 0.3% for treatment of conjunctivitis caused by adenovirus.</brief_summary>
	<brief_title>Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus</brief_title>
	<detailed_description>To evaluate the efficacy and tolerability of ganciclovir ophthalmic gel for the treatment of conjunctivitis comparing to placebo (ophthalmic gel). Visual acuity test and slit lamp examination (biomicroscopy) will be performed at each visit to assess the signs/symptoms and the regression of the disease.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Conjunctivitis, Inclusion</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Patients with eye disease with a clinical diagnosis of adenovirus conjunctivitis. Patients of both gender aged over 18 years. Patients who are not pregnant or nursing. Patients able (legally and mentally) to understand and sign informed consent had been signed. Patients who are in the presence of corticosteroids, either by topical ocular, periocular, intraocular or systemic, for less than 30 days of enrollment and who can not make a drug suspension. Patients with serious systemic diseases like AIDS, cancer, etc., which in the opinion of the investigator, may put the patient at risk. Patient with a single eye or vision in one eye.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Conjunctivitis</keyword>
	<keyword>adenovirus.</keyword>
</DOC>